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Abstract
Background: Systemic immune activation (inflammation) and immunosenescence develop in some people with
advancing age. This process, known as “inflamm-aging,” is associated with physical frailty and sarcopenia.
Meanwhile, successful antiretroviral therapy has led to a growing number of older HIV-1-infected individuals who
face both age-related and HIV-1-related inflammation, which may synergistically promote physical decline, including
frailty and sarcopenia. The purpose of our study was to determine if inflammation during treated HIV-1 infection
worsens physical impairment in older individuals.
Methods: We determined the severity of HIV-associated inflammation and physical performance (strength and
endurance) in 21 older HIV-infected individuals (54–69 years) receiving suppressive antiretroviral therapy, balanced for
confounding variables including age, anthropometrics, and co-morbidities with 10 uninfected control individuals.
Biomarkers for microbial translocation (lipopolysaccharide [LPS]), inflammation (soluble CD14 [sCD14], osteopontin, C-
reactive protein [CRP], interleukin-6 [IL-6], soluble ICAM-1 [sICAM-1] and soluble VCAM-1 [sVCAM-1]), and coagulopathy (D-
dimer) were assayed in plasma. Activation phenotypes of CD4+T cells, CD8+ T cells and monocytes were measured by
flow cytometry. Physical performance was measured by 400 m walking speed, a short physical performance battery
[SPPB], and lower extremity muscle strength and fatigue.
Results: Overall physical function was similar in the uninfected and HIV-infected groups. Compared to uninfected
individuals, the HIV-infected group had elevated levels of sCD14 (P < 0.001), CRP (P < 0.001) and IL-6 (P = 0.003) and an
increased frequency of CD4+ and CD8+ T cells with an immunosenescent CD57+ phenotype
(P = 0.004 and P = 0.043, respectively). Neither plasma inflammatory biomarkers nor CD57+ T cells correlated with CD4+ T
cell counts. Furthermore, none of the elevated inflammatory biomarkers in the HIV-infected subjects were associated with
any of the physical performance results.
Conclusions: When age-related co-morbidities were carefully balanced between the uninfected and HIV-infected groups,
no evidence of inflammation-associated physical impairment was detected. Despite careful balancing for age, BMI,
medications and co-morbidities, the HIV-infected group still displayed evidence of significant chronic inflammation,
including elevated sCD14, CRP, IL-6 and CD57+ T cells, although the magnitude of this inflammation was unrelated to
physical impairment.
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Background
Antiretroviral treatment (ART) has dramatically increased
the life expectancy of HIV-infected individuals. By 2015,
more than one half of HIV-infected individuals are pro-
jected to be over 50 years old [1]. This increased life expect-
ancy has prompted questions about how aging with HIV-1
infection combined with HIV treatments might interact to
impact active life expectancy (e.g., having adequate mobility
to function as a member of the community).
HIV-1 infection causes systemic immune system acti-
vation fostered by a complex array of insults [2, 3]. The
immune activation markers that are detected in HIV-1
infection are typically also elevated with increased age in
the absence of HIV infection [3–5]. Similar to aging,
HIV infection is associated with the premature develop-
ment of cardiovascular disease, thromboembolic disease,
type 2 diabetes, cancer, neurocognitive decline, end-
organ disease and frailty even when effective ART is im-
plemented [3, 5, 6].
In HIV infection, chronic stimulation by LPS and
other substances emanating from a leaky intestinal bar-
rier leads to the activation of innate immune cells, in-
cluding monocytes and macrophages, which can be
measured in sera based on the levels of the LPS-binding
protein soluble CD14 [sCD14] [7–9], and sCD14 levels
remain elevated even with prolonged therapy [10]. Not-
ably, sCD14 has been implicated as a biomarker for the
risk of non-AIDS mortality among HIV-infected subjects
[11]. Additional markers of innate immune activation,
including interleukin-6 [IL-6] and the acute phase mol-
ecule C-reactive protein [CRP], are also predictive of
non-AIDS HIV mortality [12, 13]. Elevation of the co-
agulation factor D-dimer is independently associated
with cardiovascular disease [14] and mortality in HIV in-
fection [12]. The monocyte chemotactic protein osteo-
pontin [OPN] is persistently elevated in HIV-1 infection
[15] and is further increased in HIV-associated dementia
[16]. Inter-cellular adhesion molecule-1 [ICAM-1] and
vascular cell adhesion protein-1 [VCAM-1] are cleaved
to their soluble forms following the activation of leuko-
cytes or vascular endothelium. Both sICAM-1 and
sVCAM-1 are elevated in HIV infection [17] and associ-
ated with endothelial activation and/or an increased risk
of cardiovascular disease [18–21].
In addition to innate immune activation, adaptive im-
mune activation is a hallmark of both aging and HIV-1
infection. Most notably, both advancing age and HIV-1
infection are associated with an increased frequency of
memory CD4+CD45RA−CD45RO+ T cells as well as ex-
panded CD4+CD57+ and CD8+CD57+ T cell populations.
CD57-bearing T cells possess a unique inflammatory
senescent phenotype, whereby the cells are able to pro-
duce large amounts of inflammatory cytokines such as
TNF but demonstrate impaired proliferation [22, 23]. In
both aging and HIV-1 infection, the direct cause of
CD57+ T cell accumulation is unclear, although chronic
viral replication, for example human cytomegalovirus,
may drive the expansion of CD57 cells through immune
attrition [24].
The proper structure (tissue composition) and func-
tion (strength & endurance) of the lower extremities is
vital for maintaining mobility in late life. However, a
paucity of research has investigated mobility functions
and their determinants in HIV-infected older adults. In-
flammation may provide a common link between HIV
infection, aging and frailty. Both chronic HIV-1 infection
(treated and untreated) and aging-associated frailty are
characterized by elevated levels of pro-inflammatory cy-
tokines such as TNF and IL-6 [12, 25–27]. How the ef-
fects of HIV-1 infection, aging and inflammation
combine to affect physical function and body compos-
ition remain mostly unknown.
Here, we determined the magnitude of HIV-associated
inflammation while accounting for the traditional risk
factors for age-related illness. A key objective was to
examine the relationships between biomarkers of inflam-
mation and physical function and to understand whether
HIV-1 infection compounds the relationship between
chronic inflammation and functional decline in older in-
dividuals. The cohort included older HIV-infected indi-
viduals (average age = 59.7 years, range 54–69 years)
undergoing suppressive ART, compared to non-infected
participants who were closely balanced for confounding
variables including age, anthropometrics (body mass
index), co-morbidities (e.g., diabetes and cardiovascular
disease) and smoking status.
Methods
Subject inclusion/exclusion and enrollment
Twenty-one HIV-infected participants were recruited
from the Gainesville Veterans Administration HIV clinic
and the community at large. All of the participants pro-
vided written informed consent based on documents ap-
proved by the University of Florida Institutional Review
Board. The protocols at Malcom Randall VA Medical
Center are approved concurrently through the University
of Florida IRB. The inclusion criteria were as follows:
age ≥ 54 years old, well-controlled HIV on ART for at
least 12 months, CD4 > 100 cells/ul and plasma HIV
RNA < 5,000 copies. Combination regimens were ei-
ther NRTI-based (Efavirenz + FTC and tenofovir; one
case was treated with Efavirenz + abacavir) or protease
inhibitor (PI)-based (atazanavir, ritonavir, fosamprena-
vir, saquinavir or darunavir + FTC and tenofovir). At
the time of the study, 20 HIV-infected subjects had
plasma HIV RNA below 50 copies/ml (the cutoff for
the assay); one subject had an HIV RNA level of 208
copies per ml. The CD4+ T cell counts in the HIV-
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infected subjects were typically above 500/mm3
(mean = 560, SD = 243). Subjects were excluded from
the study for any of the following criteria: active
AIDS-defining illness, taking stavudine or zidovudine,
hepatitis B or C infection, severe arthritis, uncon-
trolled hypertension, unstable angina, severe congest-
ive heart failure, low body mass index (<20 kg/m2),
poorly controlled diabetes, treatment for cancer in
the previous 6 months, peripheral vascular disease,
Parkinson’s disease, multiple sclerosis, amyotrophic
lateral sclerosis, renal failure, use of anabolic steroids,
cognitive impairment identified as having a Mini-
Mental State Exam Score < 24, or inflammatory dis-
ease (rheumatoid arthritis, inflammatory bowel dis-
ease, among others). It was expected that there would
be increased inflammation in the HIV-infected group,
and elevated sCD14 levels have been widely reported
as a common feature of HIV-related inflammation
[11]. With the goal of determining how inflammation
relates to physical composition/function, we powered
the study on plasma sCD14 levels. Ten HIV-
uninfected control participants were recruited after
screening the HIV-infected subjects for plasma levels
of sCD14. The mean sCD14 level of 21 HIV-infected
subjects was 1,892 ng/ml (SD = 394). Using α = 0.05,
n = 9 provides 80 % power to detect a 25 % difference
in sCD14 levels between the groups. HIV-infected
subjects frequently develop age-related co-morbidities
such as cardiovascular disease and respiratory disease,
so a ‘healthy’ non-HIV infected control group would
not be suitable for comparison. A self-report ques-
tionnaire was used to assess co-morbidities including
cardiovascular conditions (controlled hypertension,
previous hospitalization for myocardial infarction,
pacemaker, stroke or abnormal heart rhythm) or re-
spiratory conditions (shortness of breath, asthma or
recent chest congestion). Control participants were
recruited from the community, enrolled after testing
negative for HIV, and balanced to the HIV cases
based on average age, body mass index, and smoking
status, as well as the frequency of active diabetes, car-
diovascular conditions and pulmonary conditions
(Table 1). Following the balancing approach, there
were no significant differences between the groups in
terms of age, BMI, chronic diseases or the use of
non-HIV medications related to chronic disease.
Measurement of plasma biomarkers
Whole blood samples were collected in sterile Vacutai-
ner™ (Becton Dickinson, Franklin Lakes, NJ) acid citrate
dextrose tubes and processed within 12 h. The PBMC
and plasma samples were stored at −180 °C in liquid ni-
trogen and −80 °C, respectively, in non-pyrogenic poly-
propylene cryovials (Nunc Cryotubes™) [28]. LPS levels
were quantified using the Limulus Amebocyte Lysate
[LAL] chromogenic assay (Lonza Inc., Allendale, NJ) as
previously described [28]. The plasma samples were di-
luted 1:4 in 0.15 M NaCl prior to analysis, and the lower
limit of detection was 0.1 endotoxin units [EU] per milli-
liter. The following soluble markers of immune and
endothelial activation were measured by ELISA: sCD14,
osteopontin [OPN], C-reactive protein [CRP], soluble
ICAM-1 [sICAM-1], sVCAM-1 (R&D Systems Inc.,
Minneapolis, MN), and IL-6 (BD Biosciences, San Diego,
CA). The coagulation marker D-dimer was measured by
ELISA (American Diagnostica GmbH, Stamford, CT).
Flow cytometry analysis of cell surface phenotypes
The following flow cytometry antibodies were purchased
from BD Biosciences (San Jose, CA): anti-CD3-PE Cy7,
anti-CD4-Alexa488, anti-CD8-PacBlu, anti-CD28-PE,
anti-CD57-APC, anti-CD45RO-Alexa 700, anti-HLA-
DR-APC, anti-CD14-PacBlu, anti-CD11a-FITC, anti-
CD16-PE-Cy7, anti-CD163-PE, anti-CD62L-APC, and
anti-CD86-Alexa 700. Two multi-color panels were used
for T cells, and two panels were used for monocytes.
Data were collected using a BD LSRII flow cytometer
and analyzed with FCS Express software (DeNovo Soft-
ware, Los Angeles, CA).
400 m rapid walk
Participants were asked to walk 400 m (20 m per lap) at
a rapid pace as described elsewhere [29]. Walking speed
was calculated as the distance walked divided by the






Age* years 62.5 (58–69) 59.7 (54–69) 0.100a
BMI* kg/m2 29.3 (24.8–39.5) 30.1 (20.7–71.8) 0.640a
Chronic disease
Respiratory 30 % 33 % 1.000b
Cardiovascular 90 % 62 % 0.205b
Diabetes 30 % 38 % 1.000b
Current Smoker 20 % 24 % 1.000b
Non-HIV medications
Aspirin regimen 50 % 43 % 1.000b
Hypertension 50 % 76 % 0.222b
Cholesterol 90 % 71 % 0.379b
Glucose control 30 % 28 % 1.000b
HIV medications
NNRTI N/A 57 % N/A
NRTI N/A 62 % N/A
PI N/A 33 % N/A
*Mean (range), N/A not applicable; aMann-Whitney U-test, bFisher’s exact test
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time elapsed. At the end of each lap, the participants
were asked about their physical exertion on a 0 (none)
to 10 (highest) scale [30]. Lap variability may indicate fa-
tigue and was calculated as the standard deviation in
split times for each lap.
Short physical performance battery (SPPB)
The SPPB test is a common measure of physical per-
formance in older adults and is described elsewhere [31].
Briefly, the test consists of timed measures of standing
balance in three positions (side by side position, semi
tandem position, and tandem position), walking speed
over 4 m, and time to stand up and sit down 5 times in
a chair as quickly as possible. Each of the 3 performance
measures was assigned a score ranging from 0 to 4 ac-
cording to normative data published elsewhere [31], with
4 indicating the highest level of performance, and 0
representing an inability to complete the test. A sum-
mary score was created by adding each performance
score; the summary score therefore ranges from 0 to 12.
Excluding the balance test, values were reported for the
speed (or time) to complete each task and score.
Lower extremity tissue composition
T1-weighted 3D-magnetic resonance imaging (MRI) was
used to quantify the tissue volumes of the right leg using
a Phillips 3.0 Tesla magnet (Philips Medical Systems,
Bothell, WA) as described previously [32]. Muscle, sub-
cutaneous adipose tissue (SAT), and inter-muscular adi-
pose tissue (IMAT) were measured volumetrically over
20 contiguous axial slices (10 in the mid-thigh and 10 in
the mid-calf region) as previously described by our
group [33]. Values are expressed as the absolute volume
in centimeters cubed (cm3) and as a percent of the total
volume. MRIs were collected for 18 HIV cases and 10
non-infected controls.
Lower extremity muscle strength and fatigue
Maximal knee extension and flexion isokinetic peak
torque were measured using a Biodex isokinetic dyna-
mometer (Shirley, NY). Participants were asked to
complete 50 concentric contractions at 90°/s with their
right leg. The peak torque (in Newton-meters) and total
work (in joules) achieved during the trials was used for
the data analyses. A fatigue index was calculated as the
change in muscle work (in joules) during the first 16
repetitions (the 1st third) compared to the last 16 repeti-
tions (the last 3rd). A negative value indicated a decrease
in muscle work capacity in the final 16 repetitions.
Statistical analyses
For all parameters, outliers were detected using the
Grubb’s extreme studentized deviate [ESD] method with
an alpha value set at 0.01. After the outliers were
removed, each parameter was tested for a normal distri-
bution using the D’Agostino & Pearson omnibus nor-
mality test. Normally distributed parameters were
compared using unpaired t-tests, and non-normally dis-
tributed parameters were compared by Mann–Whitney
U-tests. A total of 5 outlier values were detected and re-
moved; when the outliers were re-introduced and the
analyses were re-run, no qualitative differences in out-
comes or new significant differences were detected. All
of the reported data excluded outliers. Pearson’s correl-
ation and simple linear regression were used to deter-
mine the relationships between two variables.
Results
Innate immune activation in older HIV-infected
individuals
To determine the severity of innate immune activation,
a panel of plasma biomarkers was assessed. LPS levels
were similar in HIV-infected individuals and uninfected
individuals (Table 2). Likewise, some markers of immune
activation/coagulation, including OPN and D-dimer,
were similar between the un-infected and infected
groups. Trends toward elevated sICAM1 (P = 0.022) and
sVCAM1 (P = 0.009) were observed, but neither factor
reached the significance threshold of P = 0.006 (adjusted
for multiple comparisons). There were, however, signifi-
cantly higher levels of sCD14, CRP and IL-6 in the HIV-
infected group compared to the uninfected group.
We then compared individual markers of immune ac-
tivation to determine whether elevated levels of soluble
factors were correlated or independently regulated.
When a correlation matrix was applied, no association
between plasma LPS and any soluble marker of inflam-
mation was found (Table 3). When each inflammatory
marker was compared to the panel of markers, only
sVCAM1 and sICAM1 displayed the expected strong
positive correlation (r = 0.700, P < 0.001).
Table 2 Elevated inflammation biomarkers but similar microbial
translocation in older HIV-infected subjects
Uninfected n = 10 HIV n = 21 P value*
LPS EU/ml 0.37 (0.30/0.44) 0.34 (0.26/0.42) 0.638
sCD14 ng/ml 1154 (993/1315) 1892 (1716/2069) ≤0.001
OPN ng/ml 38.9 (32.8/44.9) 45.7 (37.4/54.0) 0.257
sICAM-1 ng/ml 631 (510/766) 1086 (815/136) 0.022
sVCAM-1 ng/ml 49.0 (34.5/63.6) 71.4 (61.6/81.2) 0.009
CRP ng/ml 650 (369/931) 4582 (2675/6488) ≤0.001
IL-6 pg/ml 0.42 (0.08/0.92) 2.10 (1.19/3.01) 0.003
D-dimer ng/ml 104.5 (4.2/204.8) 229.1 (72.6/385.6) 0.417
All values are means (5/95 % CI). *Mann–Whitney U-test. The underlined values
are statistically significant at P < 0.006 (adjusted for multiple comparisons); the
Italicized values show a trend toward statistical significance at P < 0.05
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Reduced monocyte frequency in HIV-infected subjects
Because HIV infection results in elevated plasma levels
of sCD14, we sought to determine whether the circulat-
ing monocytes displayed an activated phenotype. Total
PBMCs (lymphocytes and monocytes) were analyzed for
the frequency of CD14+ monocytes in uninfected control
and HIV-infected subjects (Fig. 1a). The frequency of
CD14+ monocytes in the total PBMCs was significantly
lower in HIV-infected subjects (Fig. 1b). Monocyte acti-
vation was measured based on the expression of the cell
surface proteins CD11a, CD16, CD163, CD62L, CD86
and HLA-DR. Despite significantly elevated sCD14 levels
in the plasma of HIV-infected subjects, there was no evi-
dence that any of the activation markers differed in per-
ipheral blood monocytes (Fig. 1c).
T cell activation in HIV-infected subjects
T cell senescence is characterized by the loss of CD28
expression and the increased expression of CD57 in
CD4 or CD8 T cells [23, 34]. We found that in older
HIV-infected subjects, the frequency of CD57+ T cells
(both CD4+ and CD8+) was significantly elevated in
comparison to uninfected subjects (Fig. 2a and d).
The CD57+ cells were further classified based on the
expression of CD28. Among CD4+ cells, the CD57+
CD28+ subset accounted for the difference observed
in HIV-infected subjects (P = 0.002) (Fig. 2b) whereas
no difference in the CD4+ CD57+ CD28− population
was found between uninfected and HIV-infected sub-
jects (P = 0.849) (Fig. 2c). In contrast, among CD8+ T
cells, the CD57+ CD28+ populations were similar be-
tween the uninfected and HIV groups (P = 0.612)
(Fig. 2e), but a higher frequency of CD8+ CD57+
CD28− T cells was observed in the HIV-infected
group (P = 0.023) (Fig. 2f ). The frequencies of CD4+
CD57+ CD28+ and CD8+ CD57+ CD28− cells were
positively correlated in the HIV-infected subjects (r =
0.512, P = 0.025) (data not shown).
One of the strongest correlates for CD4+ T cell decline
in HIV infection is the increased frequency of memory/
effector CD4+ CD45RO+ T cells and a corresponding
deficit in CD4+ CD45RA+ naïve T cells [28, 35, 36]. In
this cohort of older ART-treated HIV subjects, there was
no difference in the frequency of CD4+ CD45RO+ T cells
between the groups (Fig. 3a), yet the frequency of these
memory/effector cells was inversely correlated with the
peripheral blood CD4+ T cell counts in the HIV-infected
individuals (r = −0.638, P = 0.008) (Fig. 3b). Neither the
CD4+ CD57+ CD28+ nor CD8+ CD57+ CD28- T cell fre-
quency was associated with the CD4+ T cell counts
(Fig. 3c and d).
Physical composition and performance
Lower extremity tissue composition measurements were
available for 18 of the 21 HIV-positive participants
(Table 4). There were no significant differences in leg
tissue volumes, and the measures of subcutaneous and
intramuscular adiposity were similar between the HIV
and control groups. Muscle strength and fatigue were
similar between the control and HIV-infected groups,
with no difference in knee extension peak torque, knee
flexion peak torque, knee extension total work, knee
flexion total work, knee extension fatigue index or knee
flexion fatigue index.
The average SPPB score for the control group was
11.6 (0.51), whereas the HIV group demonstrated a score
of 10.7 (1.9) (p = 0.167). When the components of the
performance battery were examined separately, the HIV-
infected subjects required more time to complete five
chair stands compared to the uninfected controls (12.1 s
vs 10.2 s, P = 0.047), but otherwise both groups were
similar across the individual components of the battery.
Finally, both the control and HIV groups showed similar
performances in the rapid walking test, with no signifi-
cant differences in 400-meter gait speed, average exer-
tion or maximal exertion. No differences were observed
for peak knee extension and flexion or total knee exten-
sion and flexion. Overall, the physical performance of
the control and HIV-infected groups was remarkably
similar. Across all subjects and within HIV+ and control
groups, exhaustive correlation analyses were performed
to compare each HIV-associated inflammatory bio-
marker (sCD14, CRL, IL-6, CD57+ T cells) with each
measure of physical composition and performance. No
significant associations were detected for any of the
comparisons (data not shown). Thus, inflammation asso-
ciated with HIV is not related to physical composition
or function in this cohort of older-aged individuals.
Discussion
Both HIV infection and normal aging in the absence of
HIV-1 infection are associated with chronic inflamma-
tion that negatively impacts overall health. Frailty de-
velops earlier in HIV-infected individuals than
uninfected individuals [37, 38], and a suspected source
of increased frailty is chronic inflammation which
Table 3 Correlations between plasma inflammation biomarkers
sCD14 CRP IL-6 sICAM1 sVCAM1
LPS 0.306 −0.077 −0.240 −0.070 −0.116
sCD14 0.395 −0.076 0.456 0.217




Pearson correlation r values, underlined = P < 0.006 (corrected for
multiple comparisons)
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develops early in HIV-1 infection [39]. In non-HIV-1-in-
fected older persons, there is a well-established correl-
ation between the biomarkers IL-6, TNF and CRP and
frailty, as demonstrated in the Newcastle 85+ study [40],
although no association between immunosenescence
and frailty was detected. In HIV-1 infection, the VACS
index, a multi-parameter score that combines bio-
markers for HIV-1 disease and organ system injury but
not inflammation, predicts frailty [41]. Here, we investi-
gated how HIV infection augments the inflammation
that occurs normally in older individuals with the goal
of understanding whether potentially additive inflamma-
tory effects of HIV-1 and advancing age accelerate the
development of frailty. Our understanding of the effects
of HIV-1 and advancing age on systemic inflammation
may be confounded by additional factors including obes-
ity, age-related co-morbidities, behaviors (e.g., smoking)
and non-HIV medications. We carefully balanced HIV-
1-infected and un-infected subjects for these factors and
found that HIV-1 infection, even with suppressive anti-
retroviral therapy, is associated with a number of unique
inflammatory phenotypes compared to a control group
with similar co-morbidity and medication profiles. As a
population, the HIV-1-infected group had significantly
elevated levels of plasma sCD14, CRP and IL-6 com-
pared to the uninfected controls. Although they failed to
reach statistical significance, modestly elevated levels of
sICAM1 and sVCAM1, markers of endothelial activa-
tion, were observed in the HIV-infected subjects. Our
previous studies in infected and uninfected young adults
revealed similar differences in sVCAM levels [42].
Based on our previous work and that of others [7, 9,
28, 43–47], we hypothesized that plasma LPS levels
would be elevated in older HIV-infected subjects
Fig. 1 Reduced frequency of monocytes among PBMCs from HIV-infected subjects. a PBMC samples were analyzed by flow cytometry by first
gating on the total mononuclear cells and then measuring the frequency of CD14+ cells for each individual (representative subjects). b The
frequency of CD14+ monocytes among PBMCs from 21 HIV-infected subjects was compared to that of 10 uninfected controls using unpaired
t-tests. c Using flow cytometry, the mean fluorescence intensity for a panel of monocyte maturation/activation markers was
determined for CD14+ cells. No differences were found between the groups
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compared to uninfected subjects, however, LPS levels
were similar in both groups. Our previous studies of mi-
crobial translocation focused on much younger individ-
uals (infants and children), among whom there were
clear differences in LPS levels in HIV-1-infected children
compared to uninfected children [28]. The similar levels
of plasma LPS among the uninfected and HIV-1-
infected older individuals was surprising, but we can
speculate that there may be age-related differences in in-
testinal permeability and microbial translocation (even
in the absence of HIV-1 infection) that mask the bio-
markers of gut pathology that are easily detected in
younger cohorts. Alternatively, co-morbidities such as
diabetes, heart disease or kidney disease, which were
prevalent among both the HIV-infected and uninfected
groups, may be associated with microbial translocation.
For example, endotoxemia is associated with atheroscler-
osis in non-HIV-infected subjects [48].
Elevated levels of plasma sCD14 are clearly associated
with poorer health status and health outcomes in HIV
patients [7, 11, 49]. While the source of sCD14 is attrib-
uted to systemic monocyte/macrophage activation, there
is little evidence to implicate peripheral blood mono-
cytes versus tissue macrophages in the elevated produc-
tion of sCD14. One recent study in younger subjects
(median age = 41 years) found a positive correlation be-
tween plasma levels of IL-6, D-dimer, CRP, or sCD163
and multiple phenotypic alterations in peripheral blood
monocytes, including the frequency of CD16+ mono-
cytes [50]. We found no evidence of monocyte pheno-
typic alterations in HIV-infected subjects despite
markedly elevated plasma levels of sCD14. We did find,
however, that HIV-infected subjects had a reduced fre-
quency of peripheral blood monocytes compared to un-
infected subjects. Whether the association between high
sCD14 and a low frequency of circulating monocytes is
due to an increased rate of monocyte extravasation or
apoptosis or alternatively to reduced production from
bone marrow precursors remains unknown. Our previ-
ous study showed that human peripheral blood mono-
cytes produce relatively higher levels of sCD14 in
comparison to macrophages, yet only macrophages
responded to LPS by releasing more sCD14 [51]. To-
gether, these findings suggest that elevated sCD14 in
Fig. 2 Increased frequency of CD57-expressing CD4+ and CD8+ T cells in HIV-infected subjects. PBMC samples were analyzed by flow cytometry
by first gating on the total mononuclear cells and then on the CD3+ T cells. The frequency of CD57+ cells among the (a) total CD4+ T cells, (b)
CD28-expressing CD4+ T cells or (c) CD28-negative CD4+ T cells was determined. Next, the frequency of CD57+ cells among the (d) total CD8+ T
cells, (e) CD28-expressing CD8+ T cells or (f) CD28-negative CD8+ T cells was determined using Mann–Whitney U-tests. The error bars
represent ± 1 SD
Wallet et al. BMC Immunology  (2015) 16:43 Page 7 of 11
older individuals may originate from tissue macrophages
rather than monocytes.
The expansion of CD57-expressing T cells is typical of
both HIV infection and advancing age [34]. In CD57+
cells specific for HIV antigens, replicative senescence
arises from chronic antigenic exposure; this effect is
similar to that observed in chronic infection with cyto-
megalovirus (CMV) associated with an increased fre-
quency of both CD4+ and CD8+T cells expressing CD57
[52]. In healthy populations, the proportion of CD8
+CD57+T cells expands with increasing age [53]. The
combined effects of age and CMV infection result in an
accumulation of CD8+ CD57+ T cells lacking the co-
stimulatory molecule CD28 [54]. We observed a signifi-
cant increase in the proportion of CD8+ CD28− CD57+
but not CD8+ CD28+ CD57+ T cells in the HIV cohort.
The CMV status of both HIV-infected and control
groups was unknown, so the cause of expanded senes-
cent CD8+ T cells requires further investigation.
Similar to CD8+ T cells, the expansion of CD4+ CD57+
CD28− T cells is associated with chronic viral infections
[55–57]. We found an increase in the frequency of CD4+
CD57+ CD28+ T cells in HIV-infected subjects but no
difference in CD4+ CD57+ CD28− T cells. Expansion of
CD57-expressing T cells occurred independently of the
total CD4 T cell number in HIV-infected subjects. In-
stead, the increased frequency of memory CD4+
CD45RO+ T cells was associated with decreased CD4+ T
cell numbers. This finding is in accordance with another
study showing that increasing age and the concomitant
reduced production of naïve CD4+ T cells, rather than
the expansion of senescent CD57+ T cells, underlies the
deficit in CD4 T cell reconstitution observed in younger,
treated HIV patients [24].
We anticipated that HIV disease would result in some
degree of frailty and/or reduced physical performance
compared to similarly-aged uninfected control subjects.
Frailty is a common trait of HIV-1 infection and has
been linked to numerous causes including chronic in-
flammation, polypharmacy, and coagulopathy [39, 58].
Here, the control and HIV groups demonstrated nearly
identical physical characteristics with similar leg tissue
volume and adiposity. Strength, fitness and fatigue mea-
sures were also highly similar between the groups.
Frailty in HIV-1 infection is strongly correlated with a
high viral load and CD4+ T cell decline [38, 41], whereas
lipodystrophy syndrome and fat redistribution are asso-
ciated with combination antiretroviral therapy [59]. The
patients in our study had well-controlled viremia and
stable CD4+ T cell counts, which may in part explain the
similarities in leg musculature between the uninfected
and infected groups. It is well established that antiretro-
viral therapy can cause redistribution of limb fat to the
trunk [59] or increased visceral fat within the limbs [60],
but no change in leg adiposity was observed in our HIV-
1-infected group. It is possible that the variability in
measurable lipodystrophy in the HIV-1 infected individ-
uals (estimates range from 13 to 70 % [59]) is too great
Fig. 3 Frequency of CD45RO-expressing memory CD4+ T cells, but not CD57+ CD4+ T cells, is associated with CD4+ T cell decline. PBMC samples
were analyzed by flow cytometry by first gating on the total mononuclear cells and then on the CD3+ T cells. The frequency of (a) CD4+ CD45RO
+ T cells was then determined. The correlations between total peripheral blood CD4+ T cell counts and (b) T cells CD4+ CD45RO+ T cells, (c) CD4+
CD28+ CD57+ T cells, or (d) CD8+ CD28− CD57+ T cells were determined (Pearson correlation)
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to observe changes on our relatively small cohort. In
addition, exclusion of subjects taking the NRTI drugs
stavudine or zidovudine may explain the similarities in
adiposity, because HIV-associated lipoatrophy has been
related to exposure to these drugs [61].
Despite strong evidence for increased inflammation in
the HIV-1 group, the infected and uninfected groups
had similar muscle and physical performance character-
istics. Thus, although inflammation is a characteristic of
aging-related frailty and HIV-1 infection, our study sug-
gests that increased inflammation in older HIV-1-
infected individuals causes no greater frailty than what is
found in similarly aged uninfected individuals. Ours is
the first study that we know of where older uninfected
and HIV-1-infected individuals were carefully balanced
for age-related co-morbidities and medications to specif-
ically assess the role of HIV-associated inflammation in
frailty. A major limitation of our conclusion is that the
study size is small; this work should be repeated in lar-
ger studies. Nonetheless, inflammation was profoundly
elevated in the HIV-1-infected group, so we accept this
as convincing evidence that inflammation alone does not
always lead to frailty.
Conclusions
HIV infection is thought to augment the inflammatory
consequences of advancing age, with many of the health
challenges of old age being faced by far younger infected
adults. However, HIV infection is no longer a disease of
youth. Improvements in therapy are resulting in a
Table 4 Physical composition and performance
Control (N = 10) HIV (n = 21) P-value
Leg tissue volume (values in cm3) a
Total circumference 651 (170) 637 (170) 0.841
Muscle tissue 353 (69.6) 336 (52.8) 0.483
Subcutaneous adipose tissue 185 (105) 155 (116) 0.512
Inter-muscular adipose tissue 97.2 (25.8) 102 (26.2) 0.601
Leg tissue percent of total circumference a
Muscle tissue 54.8 (4.2) 54.3 (8.8) 0.875
Subcutaneous adipose tissue 28.0 (14.3) 22.6 (10.0) 0.259
Inter-muscular adipose tissue 15.1 (2.7) 16.4 (3.3) 0.315
Thigh muscle strength & fatigue
Knee extension peak torque (Nm) 96.4 (40.1) 103.9 (30.4) 0.562
Knee flexion peak torque (Nm) 50.7 (22.3) 53.7 (20.0) 0.705
Knee extension total work (joules) 3039 (1453) 3396 (967) 0.422
Knee flexion total work (joules) 1552 (800) 1561 (744) 0.977
Knee extension fatigue index (joules) −704 (600) −781 (581) 0.735
Knee flexion fatigue index (joules) −288 (355) −322 (294) 0.784
SPPB
4-meter gait speed (m/sec) 1.11 (0.10) 1.0 (0.18) 0.102
4-meter gait speed score (range: 0–4) 4 (0) 3.8 (0.51) 0.253
Time to complete 5 chair stands (sec) 10.2 (2.1) 12.1 (2.4) 0.047
Chair stand score (range: 0–4) 3.6 (0.51) 3.0 (0.97) 0.105
Balance score (range: 0–4) 4 (0) 3.85 (0.65) 0.499
Total performance score (range: 0–12) 11.6 (0.51) 10.7 (1.9) 0.167
400-meter rapid walk
400-meter rapid gait speed (m/sec) 1.42 (0.16) 1.28 (0.24) 0.126
Average exertion (range: 0–10) 1.47 (1.70) 1.14 (1.04) 0.585
Maximal exertion (range: 0–10) 2.69 (2.89) 2.03 (1.52) 0.502
Lap variability in gait speed (m/sec) 2.07 (4.21) 1.08 (0.48) 0.465
Values are means (SD) for continuous variables unless otherwise indicated
Nm Newton-meters
cm3 cubic centimeters
a Tissue volumes collected in 10 non-infected controls and 18 HIV cases
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predictable “aging up” of the HIV-infected population.
In the state of Florida, the location of our current study,
the percentage of total HIV cases among people over the
age of 50 years increased from 15 % in 2007 to 23 % in
2011 [62, 63]. As new interventions are sought to
optimize the long-term care of aging HIV patients, it is
important to appreciate the specific causes of morbidity/
mortality that impact quality and length of life. Frailty is a
characteristic of normal aging, and this process is acceler-
ated in HIV-1 infection. It has been speculated that the
common denominator between age-associated and HIV-
associated frailty is excessive inflammation. Our study ar-
gues that HIV-1-associated inflammation may not lead to
any greater frailty than what would be found in similarly-
aged uninfected individuals when controlling for other
health problems. Understanding the specific mechanisms
that underlie age-related illnesses in older HIV-1-infected
individuals will be of greater importance in the future as
this population ages.
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